TRT on TikTok: separating sex ed facts from hormone hype

What did @sexedtok actually say?

The creator, who identifies as a practitioner with 28 years of experience, argues that endocrinologists are too conservative with testosterone replacement therapy. Their specific beef: most endos won't treat below 300 ng/dL, and when they do treat, they only aim for 300-400 ng/dL. The creator's own target range is "six, seven, eight hundred" ng/dL. That's not a subtle disagreement. That's a fundamentally different clinical philosophy about what TRT is actually for.

To be clear about what's being claimed here: this practitioner is saying symptomatic men with low-normal testosterone deserve treatment, and that higher testosterone levels within what they consider a physiologic range produce dramatically better outcomes. That's worth examining carefully, because it touches on real debates in endocrinology that aren't settled.

Does the science back this up?

Partly, yes. The 300 ng/dL threshold used by many endocrinologists is somewhat arbitrary, and the research actually supports that conclusion. A 2017 analysis by Bhasin et al. in the Journal of Clinical Endocrinology and Metabolism acknowledged that there is no universally validated cutoff separating hypogonadal from eugonadal men. Symptoms don't map cleanly onto lab values, which is the core of this creator's argument, and on that point, they're not wrong.

The Testosterone Trials (TTrials), published across multiple journals between 2016-2018, showed that men over 65 with low testosterone who were treated to mid-normal range (roughly 500 ng/dL) saw improvements in sexual function, bone density, and some quality-of-life measures. However, those trials deliberately avoided pushing levels into the upper-normal range, partly out of cardiovascular caution. The creator's target of 600-800 ng/dL sits at the higher end of the reference range for young healthy men, which is defensible, but it's not the same as proven safer or demonstrably better for all patients.

What did they get wrong (or right)?

They got the symptom-based argument mostly right. Treating by symptoms alongside labs is increasingly supported, and the rigidity of the 300 ng/dL floor has legitimate critics in the literature. Endocrinology guidelines from the Endocrine Society (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism) do allow for clinical judgment in borderline cases.

Where this gets shaky is the claim that levels of 600-800 ng/dL are simply "safe" as a blanket statement. That's overconfident. Cardiovascular risk at higher testosterone levels remains contested. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found no increased major cardiovascular events with TRT in men with hypogonadism and elevated cardiovascular risk, which is reassuring. But that trial wasn't specifically examining whether pushing into upper-normal ranges confers extra benefit over mid-normal ranges. The phrase "men feel dramatically better" at higher levels is experience-based, not controlled trial-based.

• The 300 ng/dL threshold being too conservative: mostly accurate
• Symptomatic treatment being valid: accurate, supported by guidelines
• 600-800 ng/dL being definitively "safe" for all patients: overstated
• Patients feeling "dramatically better" at higher levels: plausible but unverified at population level

What should you actually know?

This is a real clinical debate, not quackery. There is a genuine divide between conservative endocrinology practice and the approach used by men's health clinics and some urologists. Neither camp has a clean evidence base that fully vindicates their position. What the research does support is individualized care: labs plus symptoms, not labs alone.

If you are a man with symptoms of low testosterone and your levels sit between 250-400 ng/dL, you are in genuinely contested territory. Some guidelines would treat you, some wouldn't. Finding a provider who evaluates symptoms seriously alongside labs is reasonable. What isn't reasonable is assuming a higher target number is automatically better, or that "aggressive" treatment is risk-free. Hematocrit, cardiovascular history, sleep apnea, and fertility goals all change the risk calculation significantly. A 28-year clinical track record is worth something, but it is not a substitute for shared decision-making based on your individual profile.